Smarter leaders trust GlobalData

Data Insights Net Present Value Model: SELLAS Life Sciences Group Inc's Galinpepimut-S

Buy the Model

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for Galinpepimut-S is expected to reach an annual total of $143 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Galinpepimut-S Overview

Galinpepimut-S is under development for the treatment of acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), solid tumor, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, colorectal cancer, triple-negative breast cancer, small-cell lung cancer, fallopian tube or primary peritoneal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, diffuse large B-cell lymphoma, follicular lymphoma, and myelodysplastic syndrome. It is formulated as an emulsion or solution and administered subcutaneously and parenterally. It is a synthetic peptide vaccine consisting of the immunogenic amino acids of the human Wilms tumor protein-1 peptides which include WT-1 A1, WT-1 122 long, WT-1 427 long and WT-1 331 long. The therapeutic candidate targets Wilms tumor protein 1 (WT1). It was also under development for the treatment of non-small cell lung cancer, renal cell carcinoma, transitional cell carcinoma, chronic myeloid leukemia (CML) and glioblastoma multiforme.

SELLAS Life Sciences Group Overview

SELLAS Life Sciences Group (SELLAS) is a late-stage clinical biopharmaceutical company that develops novel therapeutics for cancer. The company’s pipeline products include galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets the Wilms tumor 1 (WT1) protein and it treats acute myeloid leukemia, malignant pleural mesothelioma, ovarian cancer and peripheral t-cell lymphoma; and SLS009, a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor that targets diffuse large B cell lymphoma, pediatric tumors and hematologic malignancies. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), the National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York, the US.
The operating loss of the company was US$37.9 million in FY2023, compared to an operating loss of US$42 million in FY2022. The net loss of the company was US$37.3 million in FY2023, compared to a net loss of US$41.3 million in FY2022.

For a complete picture of Galinpepimut-S’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.